Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16563429 | 0.88 | ALDH1A1 (0.46) | CTSSCTSKS1PR3GABRB1GABRB2 | |
| SCHEMBL807380 | 0.85 | GABRB1 (0.47) | CTSSCTSKMMP12MMP13S1PR3 | |
| SCHEMBL21272612 | 0.85 | GABRB1 (0.47) | CTSSCTSKMMP12MMP13S1PR3 | |
| SCHEMBL844432 | 0.85 | ATM (0.56) | CTSSCTSKS1PR3ATMALDH1A1 | |
| SCHEMBL3217896 | 0.85 | ATM (0.56) | CTSSCTSKS1PR3ATMALDH1A1 | |
| SCHEMBL844431 | 0.85 | ATM (0.56) | CTSSCTSKS1PR3ATMALDH1A1 | |
| SCHEMBL5556840 | 0.84 | CXCR2 (0.50) | CTSSCTSKMMP13S1PR3GABRB1 | |
| SCHEMBL24494666 | 0.83 | ACACB (0.51) | ALDH1A1PDE2A | |
| SCHEMBL16333438 | 0.83 | PPARG (0.52) | CTSSCTSKS1PR3GABRB1GABRB2 | |
| SCHEMBL2833637 | 0.83 | PPARG (0.52) | CTSSCTSKS1PR3GABRB1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-2848618-B1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| CN-104245698-B | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2016-11-30 | — | — | CN | disclosed |
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3061754-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3026051-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-01 | — | — | EP | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2848618-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-03-18 | — | — | EP | disclosed |
| EP-2350020-B1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8361959-B2 | Spiro-imidazolone derivatives as glucagon receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361959-B2 | Spiro-imidazolone derivatives as glucagon receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| WO-2011119559-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-2185503-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016087-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | CTSS 3386/4885CTSK 4139/4885MMP12 1046/4885 |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | CTSS 3386/4885CTSK 4139/4885MMP12 1046/4885 |
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | CTSS 2706/4885CTSK 3442/4885MMP12 590/4885 |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | CTSS 3908/4885CTSK 2891/4885MMP12 4593/4885 |
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE3A, PDE5A | CTSS 3389/4885CTSK 3876/4885MMP12 719/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | CTSS 3386/4885CTSK 4139/4885MMP12 1046/4885 |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, MTNR1A | CTSS 4504/4885CTSK 4783/4885MMP12 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.